Stereospecific Resistance to N2-Acyl Tetrahydro-β-carboline Antimalarials Is Mediated by a PfMDR1 Mutation That Confers Collateral Drug Sensitivity

Overview

Journal ACS Infect Dis

Date 2025 Jan 14

PMID 39808111

Authors

Emily K Bremers

Joshua H Butler

Leticia S Do Amaral

Emilio F Merino

Hanan Almolhim

Bo Zhou

Rodrigo P Baptista

Maxim Totrov

Paul R Carlier

Maria Belen Cassera

Affiliations

Soon will be listed here.

Abstract

Half the world's population is at risk of developing a malaria infection, which is caused by parasites of the genus . Currently, resistance has been identified to all clinically available antimalarials, highlighting an urgent need to develop novel compounds and better understand common mechanisms of resistance. We previously identified a novel tetrahydro-β-carboline compound, PRC1590, which potently kills the malaria parasite. To better understand its mechanism of action, we selected for and characterized resistance to PRC1590 in . Through selection of resistance to PRC1590, we have identified that a single-nucleotide polymorphism on the parasite's multidrug resistance protein 1 (PfMDR1 G293V) mediates resistance to PRC1590. This mutation results in stereospecific resistance and sensitizes parasites to other antimalarials, such as mefloquine, quinine, and MMV019017. Intraerythrocytic asexual stage specificity assays have revealed that PRC1590 is most potent during the trophozoite stage when the parasite forms a single digestive vacuole (DV) and actively digests hemoglobin. Moreover, fluorescence microscopy revealed that PRC1590 disrupts the function of the DV, indicating a potential molecular target associated with this organelle. Our findings mark a significant step in understanding the mechanism of resistance and the mode of action of this emerging class of antimalarials. In addition, our results suggest a potential link between resistance mediated by PfMDR1 and PRC1590's molecular target. This research underscores the pressing need for future research aimed at investigating the intricate relationship between a compound's chemical scaffold, molecular target, and resistance mutations associated with PfMDR1.

References

Shihan M, Novo S, Le Marchand S, Wang Y, Duncan M . A simple method for quantitating confocal fluorescent images. Biochem Biophys Rep. 2021; 25:100916. PMC: 7856428. DOI: 10.1016/j.bbrep.2021.100916. View

Fidock D, Nomura T, Talley A, Cooper R, Dzekunov S, Ferdig M . Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000; 6(4):861-71. PMC: 2944663. DOI: 10.1016/s1097-2765(05)00077-8. View

Ding S, Ghavami M, Butler J, Merino E, Slebodnick C, Cassera M . Probing the B- & C-rings of the antimalarial tetrahydro-β-carboline MMV008138 for steric and conformational constraints. Bioorg Med Chem Lett. 2020; 30(22):127520. PMC: 7686247. DOI: 10.1016/j.bmcl.2020.127520. View

Wicht K, Mok S, Fidock D . Molecular Mechanisms of Drug Resistance in Malaria. Annu Rev Microbiol. 2020; 74:431-454. PMC: 8130186. DOI: 10.1146/annurev-micro-020518-115546. View

Cingolani P, Platts A, Wang L, Coon M, Nguyen T, Wang L . A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 2012; 6(2):80-92. PMC: 3679285. DOI: 10.4161/fly.19695. View

Bray P, Howells R, Ward S . Vacuolar acidification and chloroquine sensitivity in Plasmodium falciparum. Biochem Pharmacol. 1992; 43(6):1219-27. DOI: 10.1016/0006-2952(92)90495-5. View

Wilson C, Serrano A, Wasley A, Bogenschutz M, Shankar A, Wirth D . Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum. Science. 1989; 244(4909):1184-6. DOI: 10.1126/science.2658061. View

Reiling S, Rohrbach P . Monitoring PfMDR1 transport in Plasmodium falciparum. Malar J. 2015; 14:270. PMC: 4501111. DOI: 10.1186/s12936-015-0791-3. View

Duvalsaint M, Conrad M, Tukwasibwe S, Tumwebaze P, Legac J, Cooper R . Balanced impacts of fitness and drug pressure on the evolution of PfMDR1 polymorphisms in Plasmodium falciparum. Malar J. 2021; 20(1):292. PMC: 8247092. DOI: 10.1186/s12936-021-03823-x. View

10.

Rohrbach P, Friedrich O, Hentschel J, Plattner H, H A Fink R, Lanzer M . Quantitative calcium measurements in subcellular compartments of Plasmodium falciparum-infected erythrocytes. J Biol Chem. 2005; 280(30):27960-9. DOI: 10.1074/jbc.M500777200. View

11.

Tong J, Chandramohanadas R, Tan K . High-Content Screening of the Medicines for Malaria Venture Pathogen Box for Plasmodium falciparum Digestive Vacuole-Disrupting Molecules Reveals Valuable Starting Points for Drug Discovery. Antimicrob Agents Chemother. 2018; 62(3). PMC: 5826141. DOI: 10.1128/AAC.02031-17. View

12.

Yayon A, Cabantchik Z, Ginsburg H . Identification of the acidic compartment of Plasmodium falciparum-infected human erythrocytes as the target of the antimalarial drug chloroquine. EMBO J. 1984; 3(11):2695-700. PMC: 557751. DOI: 10.1002/j.1460-2075.1984.tb02195.x. View

13.

Meister S, Plouffe D, Kuhen K, Bonamy G, Wu T, Barnes S . Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science. 2011; 334(6061):1372-7. PMC: 3473092. DOI: 10.1126/science.1211936. View

14.

Veiga M, Dhingra S, Henrich P, Straimer J, Gnadig N, Uhlemann A . Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nat Commun. 2016; 7:11553. PMC: 4873939. DOI: 10.1038/ncomms11553. View

15.

Monteiro Junior J, Kruger A, Palmisano G, Wrenger C . Transporter-Mediated Solutes Uptake as Drug Target in . Front Pharmacol. 2022; 13:845841. PMC: 8965513. DOI: 10.3389/fphar.2022.845841. View

16.

Cowman A, Galatis D, Thompson J . Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc Natl Acad Sci U S A. 1994; 91(3):1143-7. PMC: 521470. DOI: 10.1073/pnas.91.3.1143. View

17.

Froberg G, Ferreira P, Martensson A, Ali A, Bjorkman A, Gil J . Assessing the cost-benefit effect of a Plasmodium falciparum drug resistance mutation on parasite growth in vitro. Antimicrob Agents Chemother. 2012; 57(2):887-92. PMC: 3553735. DOI: 10.1128/AAC.00950-12. View

18.

Luth M, Godinez-Macias K, Chen D, Okombo J, Thathy V, Cheng X . Systematic in vitro evolution in reveals key determinants of drug resistance. Science. 2024; 386(6725):eadk9893. PMC: 11809290. DOI: 10.1126/science.adk9893. View

19.

Si K, He X, Chen L, Zhang A, Guo C, Li M . The structure of multidrug resistance protein 1 reveals an N-terminal regulatory domain. Proc Natl Acad Sci U S A. 2023; 120(32):e2219905120. PMC: 10410737. DOI: 10.1073/pnas.2219905120. View

20.

Simon N, Voigtlander C, Kappes B, Rohrbach P, Friedrich O . PfMDR1 Transport Rates Assessed in Intact Isolated Digestive Vacuoles Reflect Functional Drug Resistance Relationship with Mutations. Pharmaceuticals (Basel). 2022; 15(2). PMC: 8875337. DOI: 10.3390/ph15020202. View